New antifungal holds promise after encouraging Phase I trial
by Edward Marks from Outbreak News Today on (#V0X8)
Cidara Therapeutics, an antimicrobial development company out of San Diego, California, has recently reported positive Phase I results of a novel antifungal agent, CD101 IV. CD101 IV is a small molecule in the echinocandin class of antifungals. Echinocandins, including Merck's Caspofungin and Pfizer's Eraxis, inhibit the enzyme 1,3-I^2 glucan synthase which is used to synthesize ["]
